Struggling with low desire and feeling disconnected from your intimate life? PT-141 (bremelanotide) is a groundbreaking peptide therapy that works directly through your brain’s natural desire pathways, not just blood flow, offering a truly unique approach to reigniting sexual wellness from the inside out.
What Are Peptides?
Peptides are short chains of amino acids – the same building blocks that make up proteins – linked together by chemical bonds. While proteins may contain hundreds or thousands of amino acids, peptides are generally smaller, typically ranging from two to about fifty amino acids in length. Because of their small size, peptides can act as highly specific signaling molecules in the body, binding to receptors on cell surfaces to trigger precise biological responses. The human body naturally produces many peptides that serve as hormones, neurotransmitters, and growth factors, regulating everything from metabolism and immune function to tissue repair, mood, and sexual response.
What Is Bremelanotide (PT-141)?
Bremelanotide, also known by its research designation PT-141 and marketed under the brand name Vyleesi, is a synthetic peptide that belongs to a class of compounds called melanocortins. Unlike the growth hormone peptides discussed in our previous blog post, bremelanotide does not target the pituitary gland’s growth hormone axis. Instead, it acts on a completely different receptor system – the melanocortin receptor system – which plays a central role in regulating skin pigmentation, appetite, energy balance, and, importantly, sexual desire and arousal.
Bremelanotide is currently the only FDA-approved melanocortin peptide for the treatment of sexual dysfunction. It was approved in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women – a condition characterized by persistently low sexual desire that causes marked personal distress or interpersonal difficulty, and that is not explained by a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication.
The History of Bremelanotide: From Tanning Peptide to Sexual Health
The story of bremelanotide begins with the melanocortins – a family of naturally occurring peptide hormones derived from a precursor molecule called pro-opiomelanocortin (POMC). The most well-known melanocortin is alpha-melanocyte-stimulating hormone (α-MSH), which regulates skin pigmentation by binding to melanocortin receptors on melanocytes.
In the 1980s and 1990s, researchers at the University of Arizona developed synthetic analogs of α-MSH to study skin tanning. One of these analogs, melanotan II (MT-II), was a cyclic peptide designed to be more potent and longer-lasting than natural α-MSH. During early clinical testing, an unexpected side effect was observed: male subjects who received MT-II experienced spontaneous penile erections. This serendipitous discovery opened an entirely new avenue of research into the melanocortin system’s role in sexual function.
Bremelanotide (PT-141) was subsequently developed by Palatin Technologies as a metabolite and refined analog of melanotan II, specifically optimized for its effects on sexual function while minimizing the tanning and other off-target effects of its parent compound. It was initially studied as an intranasal spray for male erectile dysfunction before being reformulated as a subcutaneous injection and redirected toward female HSDD – the indication for which it ultimately received FDA approval.
Mechanism of Action
Bremelanotide is a melanocortin receptor (MCR) agonist that nonselectively activates several melanocortin receptor subtypes. Its order of receptor potency is: MC1R > MC4R > MC3R > MC5R > MC2R. At therapeutic doses, binding to MC1R and MC4R is most clinically relevant.
The MC4R is the receptor most closely linked to sexual function. MC4R is predominantly expressed in the medial preoptic area (mPOA) of the hypothalamus – a brain region that is critical for the regulation of sexual desire and arousal in both males and females. Animal studies suggest that bremelanotide activates presynaptic MC4Rs on neurons in the mPOA, leading to increased release of dopamine – an excitatory neurotransmitter that plays a key role in the brain’s reward and desire pathways. By enhancing dopaminergic signaling in these brain regions, bremelanotide is thought to shift the balance of the sexual response system toward greater excitation.
This central nervous system mechanism of action is fundamentally different from that of phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) and tadalafil (Cialis), which work peripherally on blood flow to the genitals. Bremelanotide acts “upstream” in the brain, targeting desire and arousal at the neurological level rather than the vascular level.
The MC1R, the other receptor activated at therapeutic doses, is expressed on melanocytes – the pigment-producing cells of the skin. Binding at MC1R leads to increased melanin expression and skin pigmentation, which accounts for the hyperpigmentation side effect discussed below.
FDA-Approved Indication
Bremelanotide (Vyleesi) is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is estimated to affect approximately 10% of women in the United States and is the most prevalent female sexual dysfunction.
The approved dosing is 1.75 mg administered subcutaneously via autoinjector to the abdomen or thigh, at least 45 minutes before anticipated sexual activity. Patients should not exceed one dose within 24 hours, and no more than 8 doses per month is recommended. The prescribing guidelines recommend discontinuing use after 8 weeks if no benefit is observed.
Clinical Trial Evidence
The FDA approval of bremelanotide was based on the RECONNECT program – two identical, randomized, double-blind, placebo-controlled phase 3 trials enrolling a combined 1,267 premenopausal women with HSDD. The coprimary endpoints were change from baseline in the Female Sexual Function Index (FSFI) desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13.
In both studies, women taking bremelanotide demonstrated statistically significant increases in sexual desire compared to placebo (integrated studies: +0.35, P<0.001) and statistically significant reductions in distress related to low sexual desire (integrated studies: -0.33, P<0.001). Subgroup analyses showed that bremelanotide achieved significant improvements across all age, weight, BMI, and baseline testosterone subgroups, and regardless of HSDD duration or the presence of decreased arousal.
In qualitative exit interviews, women who received bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in the overall quality of their sexual activities and partner relationships – physiological responses that were not described by women in the placebo group.
A 52-week open-label extension study demonstrated sustained improvements in HSDD symptoms with no new safety signals. Most patients used bremelanotide two to three times per month.
It is important to note that while the clinical trial results were statistically significant, some experts have characterized the overall clinical benefit as modest. This is consistent with the challenges inherent in conducting clinical trials for female sexual dysfunction, including significant placebo effects and the use of subjective outcome measures.
Investigational Uses
Beyond its approved indication in premenopausal women, bremelanotide has been investigated in several other clinical contexts:
- Male Erectile Dysfunction: Bremelanotide was originally studied for male ED, initially as an intranasal spray. Phase II clinical trials demonstrated erectogenic properties, and a randomized, double-blind, placebo-controlled trial of 342 men with ED who had failed sildenafil showed that intranasal bremelanotide (10 mg) produced positive clinical results in 33.5% of patients compared to 8.5% with placebo (P=0.03), with significantly greater intercourse satisfaction. Importantly, bremelanotide’s central mechanism of action means it is not associated with the hypotension seen with PDE5 inhibitors, making it a potential alternative for men who cannot tolerate or do not respond to conventional ED therapies. However, bremelanotide is not FDA-approved for male ED.
- Obesity and Appetite Regulation: Because the MC4R plays a central role in appetite regulation in the hypothalamus, bremelanotide has been investigated for potential weight loss effects. Two phase 1 randomized controlled trials in obese women demonstrated that bremelanotide immediately reduced caloric intake and produced significant weight loss (mean 1.7 kg) within as few as 4 days of twice-daily treatment. These findings are consistent with the known biology of MC4R agonism – genetic mutations that inhibit MC4R signaling are a well-established cause of early-onset obesity, and the related MC4R agonist setmelanotide (Imcivree) is FDA-approved for certain rare genetic obesity disorders. Bremelanotide is not approved for weight management.
Side Effects
The safety profile of bremelanotide has been characterized across 43 completed clinical studies involving approximately 3,500 subjects. The most common adverse reactions reported in the phase 3 RECONNECT trials include:
- Nausea – The most frequent side effect, reported in 40% of bremelanotide-treated patients compared to 1.3% with placebo. Nausea typically occurs within one hour of dosing and lasts approximately two hours. Importantly, the incidence is highest after the first dose (21% of patients) and then declines to approximately 3% with subsequent doses. Thirteen percent of patients required anti-emetic medication, and 8% discontinued treatment due to nausea.
- Flushing – Reported in 20.3% of patients (vs. 0.3% placebo).
- Injection site reactions – Reported in 13.2% of patients, including pain, erythema, hematoma, and pruritus.
- Headache – Reported in 11.3% of patients (vs. 1.9% placebo).
- Vomiting – Reported in 4.8% of patients (vs. 0.2% placebo).
- Transient blood pressure elevation and heart rate reduction – Bremelanotide induces maximal increases of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure, peaking 2–4 hours post-dose, with a corresponding reduction in heart rate of up to 5 beats per minute. These changes typically resolve within 12 hours.
- Focal hyperpigmentation – Reported in 1% of patients receiving up to 8 doses per month, including darkening of the face, gingiva, and breasts. Patients with darker skin are at higher risk. In a study of daily dosing, 38% of patients developed focal hyperpigmentation after just 8 consecutive days. Resolution was not confirmed in all patients after discontinuation, meaning some pigmentary changes may be permanent. This effect is a direct consequence of MC1R activation on melanocytes.
The majority of adverse events were mild (31%) to moderate (40%) in intensity. No deaths occurred during the clinical development program.
Contraindications
Bremelanotide is contraindicated in patients with:
- Uncontrolled hypertension or known cardiovascular disease – Due to its transient blood pressure-elevating effects, bremelanotide is not recommended for patients at high risk for cardiovascular disease. Cardiovascular risk should be assessed before initiating therapy and periodically during treatment.
- Bremelanotide should also be avoided or used with caution in the following situations:
- Concurrent use with oral naltrexone-containing products — Bremelanotide may slow gastric emptying and significantly decrease the systemic exposure of orally administered naltrexone. This interaction could lead to naltrexone treatment failure in patients using naltrexone for alcohol or opioid addiction, with potentially severe consequences.
- Concurrent use with oral medications dependent on threshold concentrations for efficacy. Because bremelanotide slows gastric motility, it may reduce the rate and extent of absorption of certain oral medications, including antibiotics and pain medications such as indomethacin.
- Pregnancy – Bremelanotide is not indicated for use during pregnancy.
- Patients prone to hyperpigmentation – Particularly those with darker skin tones, given the risk of potentially irreversible focal pigmentary changes.
How Bremelanotide Differs From Other Sexual Dysfunction Treatments
Bremelanotide is one of only two FDA-approved medications for HSDD in premenopausal women, alongside flibanserin (Addyi). The two drugs work through entirely different mechanisms: flibanserin is a serotonin mixed agonist/antagonist taken daily as an oral tablet, while bremelanotide is a melanocortin receptor agonist administered on-demand as a subcutaneous injection. Flibanserin carries a boxed warning regarding the risk of severe hypotension and syncope when combined with alcohol, a concern that does not apply to bremelanotide, clinical studies showed no clinically significant interaction between bremelanotide and ethanol.
Bremelanotide also differs fundamentally from PDE5 inhibitors used for male ED. While PDE5 inhibitors work peripherally to enhance blood flow to the genitals, bremelanotide acts centrally in the brain to modulate desire and arousal pathways. This distinction is clinically important: bremelanotide has demonstrated efficacy in men who failed sildenafil therapy, and it is not associated with the hypotension that can occur with PDE5 inhibitors.
The Importance of a Concierge Physician in Peptide Therapy
Peptide therapies such as bremelanotide offer exciting potential, but they require the kind of attentive, personalized medical oversight that a concierge physician is uniquely positioned to provide. Unlike traditional practice models, a concierge physician maintains smaller patient panels, allowing for the dedicated time and accessibility needed to thoroughly evaluate each patient before initiating therapy, including comprehensive cardiovascular risk assessment, screening for contraindications, and a detailed review of concurrent medications for potential interactions.
With a concierge physician keeping a watchful eye over your care, dosing is carefully tailored to your individual needs, and adverse effects such as blood pressure changes or hyperpigmentation are caught early through proactive monitoring and direct, ongoing communication. Rather than navigating rushed appointments or delayed callbacks, patients benefit from the kind of responsive, relationship-driven care that ensures peptide therapy remains both safe and effective.
A concierge physician takes the time to understand your complete clinical profile and treatment goals, ensuring that therapies like bremelanotide are not only appropriate but optimized for your unique health picture. This level of individualized attention maximizes potential benefits while minimizing risks, the kind of care that simply isn’t possible without a physician who truly knows you and is readily available when questions or concerns arise.
Peptide therapy should never be undertaken without qualified medical supervision, and a concierge model offers the gold standard of that oversight.
Sources
Vyleesi. FDA Drug Label. Food and Drug Administration. Updated date: 2025-01-10. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology. 2019. Kingsberg SA, Clayton AH, Portman D, et al.
The Neurobiology of Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women. CNS Spectrums. 2022. Pfaus JG, Sadiq A, Spana C, Clayton AH.
Melanocortin Peptide Therapeutics: Historical Milestones, Clinical Studies and Commercialization. Peptides. 2006. Hadley ME, Dorr RT.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology. 2019. Kingsberg SA, Clayton AH, Portman D, et al.
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology. 2019. Simon JA, Kingsberg SA, Portman D, et al.
Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women’s Health. 2022. Clayton AH, Kingsberg SA, Portman D, et al.
Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. The Journal of Urology. 2008. Safarinejad MR, Hosseini SY.
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, Obesity & Metabolism. 2022. Spana C, Jordan R, Fischkoff S.
Sexual Dysfunction in Women. The New England Journal of Medicine. 2024. Davis SR.
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. The Annals of Pharmacotherapy. 2020. Mayer D, Lynch SE.